Previous 10 | Next 10 |
2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...
2024-02-14 02:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 6.29% on the day to $18.41. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved ...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.67% on the day to $16.47. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved...
2024-02-03 10:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.93% on the day to $5.16. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved p...
2024-01-24 13:30:02 ET Guggenheim analyst issues UNDERPERFORM recommendation for MGNX on January 24, 2024 01:00PM ET. The previous analyst recommendation was Underperform. MGNX was trading at $11.89 at issue of the analyst recommendation. The overall analyst consensus : ...
2024-01-24 13:30:02 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for MGNX on January 24, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. MGNX was trading at $11.89 at issue of the analyst recommendation. The overall analys...
2024-01-23 13:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.93% on the day to $5.16. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved p...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for MGNX on July 29, 2024 05:41AM ET. The previous analyst recommendation was Overweight. MGNX was trading at $5.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $9.00 for MGNX on 2024-07-29 05:41:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $5.55. The overall price target consensus is at $15.43 with ...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.9% on the day to $5.35. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...